0 items USD 0.00Search
Your search for "mrrpb5 global united states european union china pasireotide market research report 2019 2025" gave back 83406 results.
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Summary Publisher estimates that the Thymic Carcinoma Treatment market size will grow from xxx Million USD in 2020 to xxxx Million USD by 2025, and...
Catalog:
HYR
May 2021
Price: USD 2,000.00
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have closed. In this report, we study the drugs for...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which...
Catalog:
MRRPB5
March 2024
Price: USD 2,900.00
Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have closed. In this report, we study the drugs for...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
LPI
February 2023
Price: USD 3,660.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
LPI
February 2023
Price: USD 3,660.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
GIR
January 2023
Price: USD 3,480.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
GIR
January 2023
Price: USD 3,480.00
Citicoline (cytidine diphosphocholine, CDP-choline) is a novel nutrient with a broad spectrum of benefits for conditions associated with symptoms of...
Catalog:
MRRPB5
February 2024
Price: USD 2,900.00
